Form 8-K - Current report:
SEC Accession No. 0001104659-25-050528
Filing Date
2025-05-19
Accepted
2025-05-19 17:30:20
Documents
14
Period of Report
2025-05-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2515543d1_8k.htm   iXBRL 8-K 26093
2 EXHIBIT 99.1 tm2515543d1_ex99-1.htm EX-99.1 69216
6 GRAPHIC tm2515543d1_ex99-1img001.jpg GRAPHIC 5569
  Complete submission text file 0001104659-25-050528.txt   277568

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eyen-20250519.xsd EX-101.SCH 3014
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20250519_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20250519_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2515543d1_8k_htm.xml XML 3675
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 25965221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)